389 related articles for article (PubMed ID: 38706496)
1. Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024.
Bays HE; Kirkpatrick C; Maki KC; Toth PP; Morgan RT; Tondt J; Christensen SM; Dixon D; Jacobson TA
Obes Pillars; 2024 Jun; 10():100108. PubMed ID: 38706496
[TBL] [Abstract][Full Text] [Related]
2. Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024.
Bays HE; Kirkpatrick CF; Maki KC; Toth PP; Morgan RT; Tondt J; Christensen SM; Dixon DL; Jacobson TA
J Clin Lipidol; 2024; 18(3):e320-e350. PubMed ID: 38664184
[TBL] [Abstract][Full Text] [Related]
3. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association.
Bays HE; Toth PP; Kris-Etherton PM; Abate N; Aronne LJ; Brown WV; Gonzalez-Campoy JM; Jones SR; Kumar R; La Forge R; Samuel VT
J Clin Lipidol; 2013; 7(4):304-83. PubMed ID: 23890517
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
5. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
6. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
7. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
8. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
Després JP; Ross R; Boka G; Alméras N; Lemieux I;
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
[TBL] [Abstract][Full Text] [Related]
9. Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.
Fitch AK; Bays HE
Obes Pillars; 2022 Mar; 1():100004. PubMed ID: 37990702
[TBL] [Abstract][Full Text] [Related]
10. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
11. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
12. Residual Atherosclerotic Cardiovascular Disease Risk: Focus on Non-High-Density Lipoprotein Cholesterol.
Luo Y; Peng D
J Cardiovasc Pharmacol Ther; 2023; 28():10742484231189597. PubMed ID: 37641208
[TBL] [Abstract][Full Text] [Related]
13. Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association.
Kirkpatrick CF; Sikand G; Petersen KS; Anderson CAM; Aspry KE; Bolick JP; Kris-Etherton PM; Maki KC
J Clin Lipidol; 2023; 17(4):428-451. PubMed ID: 37271600
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial.
Ihm SH; Chung WB; Lee JM; Hwang BH; Yoo KD; Her SH; Song WH; Chae IH; Park TH; Kim JH; Jeon DW; Cho BR; Kang SH; Park SD; Lee JB; Woo JT; Lee BW; Han KA; Won KH; Kim HS; Yu JM; Chung CH; Kim HJ; Cho HC; Seung KB
Clin Ther; 2020 Oct; 42(10):2021-2035.e3. PubMed ID: 32891418
[TBL] [Abstract][Full Text] [Related]
15. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
Kones R
Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein profiles of fat distribution and its association with insulin sensitivity.
Wei D; Marrachelli VG; Melgarejo JD; Liao CT; Janssens S; Verhamme P; Vanassche T; Van Aelst L; Monleon D; Redón J; Zhang ZY
Front Endocrinol (Lausanne); 2022; 13():978745. PubMed ID: 36387872
[TBL] [Abstract][Full Text] [Related]
17. Nordic dietary patterns and cardiometabolic outcomes: a systematic review and meta-analysis of prospective cohort studies and randomised controlled trials.
Massara P; Zurbau A; Glenn AJ; Chiavaroli L; Khan TA; Viguiliouk E; Mejia SB; Comelli EM; Chen V; Schwab U; Risérus U; Uusitupa M; Aas AM; Hermansen K; Thorsdottir I; Rahelić D; Kahleová H; Salas-Salvadó J; Kendall CWC; Sievenpiper JL
Diabetologia; 2022 Dec; 65(12):2011-2031. PubMed ID: 36008559
[TBL] [Abstract][Full Text] [Related]
18. Long-term prognostic value of LDL-C, HDL-C, lp(a) and TG levels on cardiovascular disease incidence, by body weight status, dietary habits and lipid-lowering treatment: the ATTICA epidemiological cohort study (2002-2012).
Georgoulis M; Chrysohoou C; Georgousopoulou E; Damigou E; Skoumas I; Pitsavos C; Panagiotakos D
Lipids Health Dis; 2022 Dec; 21(1):141. PubMed ID: 36529737
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
